Mostrando 3 resultados de: 3
Filtros aplicados
Subtipo de publicación
Article(3)
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease
ArticleAbstract: Background: The combination of 2.5 mg rivaroxaban twice daily and 100 mg aspirin once daily comparedPalabras claves:aspirin, Coronary artery disease, Mortality , Peripheral artery disease, rivaroxabanAutores:Anand S.S., Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Branch K.R.H., Connolly S.J., Dagenais G.R., Eikelboom J.W., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Maggioni A.P., Muehlhofer E., Sharma M., Shestakovska O., Yusuf S.Fuentes:googlescopusHealth-Related Quality of Life and Mortality in Heart Failure The Global Congestive Heart Failure Study of 23000 Patients From 40 Countries
ArticleAbstract: BACKGROUND: Poor health-related quality of life (HRQL) is common in heart failure (HF), but there arPalabras claves:health status, Heart Failure, Left, prognosis, quality of life, Ventricular functionAutores:Alhabib K.F., Balasubramanian K., Bayes-Genis A., Budaj A.J., Dans A.M., Dokainish H., Dzudie A., Ezekowitz J.A., Fox K.A.A., Fukakusa B., Grinvalds A., Johansson I., Joseph P.G., Kamath D., Karaye K.M., Lanas F.T., Lund L.H., Maggioni A.P., Makubi A., McCready T., McMurray J.J.V., PATRICIO LOPEZ -JARAMILLO, Probstfield J.L., Silva-Cardoso J., Sliwa K., Temizhan A., Teo K.K., Wittlinger T., Yusuf S.Fuentes:googlescopusRivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial
ArticleAbstract: Background: Direct oral anticoagulants are administered in fixed doses irrespective of body weight,Palabras claves:Cardiovascular Risk, DOAC, prevention, rivaroxabanAutores:Berkowitz S.D., Bhatt D.L., Dyal L., Eikelboom J.W., Fox K.A.A., Guzik T.J., Muehlhofer E., PATRICIO LOPEZ -JARAMILLO, Pogosova N., Ramasundarahettige C., Yusuf S.Fuentes:googlescopus